TW202206080A - 預防及治療冠狀病毒感染的化合物及方法 - Google Patents

預防及治療冠狀病毒感染的化合物及方法 Download PDF

Info

Publication number
TW202206080A
TW202206080A TW110115949A TW110115949A TW202206080A TW 202206080 A TW202206080 A TW 202206080A TW 110115949 A TW110115949 A TW 110115949A TW 110115949 A TW110115949 A TW 110115949A TW 202206080 A TW202206080 A TW 202206080A
Authority
TW
Taiwan
Prior art keywords
acid
sars
compound
cov
antrodia
Prior art date
Application number
TW110115949A
Other languages
English (en)
Chinese (zh)
Inventor
羅吉孟
黃琤
郁彬 吳
梁惠如
林佩欣
江豪
邱韋中
Original Assignee
薩摩亞商吉亞生技控股股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 薩摩亞商吉亞生技控股股份有限公司 filed Critical 薩摩亞商吉亞生技控股股份有限公司
Publication of TW202206080A publication Critical patent/TW202206080A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110115949A 2020-05-01 2021-05-03 預防及治療冠狀病毒感染的化合物及方法 TW202206080A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063018690P 2020-05-01 2020-05-01
US63/018,690 2020-05-01

Publications (1)

Publication Number Publication Date
TW202206080A true TW202206080A (zh) 2022-02-16

Family

ID=78292168

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110115949A TW202206080A (zh) 2020-05-01 2021-05-03 預防及治療冠狀病毒感染的化合物及方法

Country Status (7)

Country Link
US (1) US12433901B2 (cg-RX-API-DMAC10.html)
EP (1) EP4142713A1 (cg-RX-API-DMAC10.html)
JP (1) JP7805010B2 (cg-RX-API-DMAC10.html)
CN (1) CN116568295B (cg-RX-API-DMAC10.html)
AU (1) AU2021264554B2 (cg-RX-API-DMAC10.html)
TW (1) TW202206080A (cg-RX-API-DMAC10.html)
WO (1) WO2021222534A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI800146B (zh) * 2021-10-21 2023-04-21 北京大學深圳研究生院 魚針草酸用於製備抑制新型冠狀病毒與變異株等感染與複製之醫藥組合物的用途
TWI917417B (zh) 2020-07-23 2026-03-11 薩摩亞商吉亞生技控股股份有限公司 治療病毒感染之方法及組合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140105928A1 (en) * 2004-01-06 2014-04-17 Paul Edward Stamets Antiviral and antibacterial activity from medicinal mushrooms
CA2481489A1 (en) * 2002-11-29 2004-06-17 Morinaga Milk Industry Co., Ltd. Cysteine protease inhibitor
TWI389699B (zh) * 2009-02-13 2013-03-21 高雄醫學大學 用於誘導細胞凋亡之樟芝子實體乙醇萃取物及其製備方法
US7919665B2 (en) 2009-02-17 2011-04-05 Conocophillips Company Mercury removal from hydrocarbons
TW201231474A (en) * 2011-01-26 2012-08-01 Univ Kaohsiung Medical Triterpenoid composition of Antrodia cinnamomea, preparation and analysis method thereof
FI126047B (en) * 2012-08-28 2016-06-15 John Eriksson Pharmaceutical compositions of anisomelic acid and their use
TWI453026B (zh) * 2013-05-14 2014-09-21 Jenisa Biotechnology Corp Ltd 魚針草萃取物及其純化物抗流感病毒之用途
US9645651B2 (en) 2013-09-24 2017-05-09 Microsoft Technology Licensing, Llc Presentation of a control interface on a touch-enabled device based on a motion or absence thereof
CN113795258B (zh) * 2019-02-25 2024-04-16 吉亚生技控股股份有限公司 抑制病毒感染的方法及组合物
US11779620B2 (en) * 2020-04-03 2023-10-10 Turtle Bear Holdings, Llc Combined fungal composition for modulating inflammatory response
CN113521060B (zh) * 2020-04-17 2022-12-06 北京大学深圳研究生院 鱼针草内酯抗新型冠状病毒的用途
WO2021218974A1 (en) * 2020-04-28 2021-11-04 Alps Biotech Co., Ltd. Uses of antrodia cinnamomea extract in manufacturing products for reducing expression and treating associated diseases of angiotensin converting enzyme 2

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI917417B (zh) 2020-07-23 2026-03-11 薩摩亞商吉亞生技控股股份有限公司 治療病毒感染之方法及組合物
TWI800146B (zh) * 2021-10-21 2023-04-21 北京大學深圳研究生院 魚針草酸用於製備抑制新型冠狀病毒與變異株等感染與複製之醫藥組合物的用途

Also Published As

Publication number Publication date
AU2021264554B2 (en) 2026-05-21
US20210338690A1 (en) 2021-11-04
CN116568295A (zh) 2023-08-08
AU2021264554A1 (en) 2023-01-05
US12433901B2 (en) 2025-10-07
CN116568295B (zh) 2026-02-13
WO2021222534A1 (en) 2021-11-04
EP4142713A1 (en) 2023-03-08
JP2023524274A (ja) 2023-06-09
JP7805010B2 (ja) 2026-01-23

Similar Documents

Publication Publication Date Title
Chiou et al. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease
US20230105838A1 (en) Method of Treating COVID-19
CN116236580B (zh) 金诺芬等老药及其组合物在抗单正链rna病毒中的应用
KR20220146558A (ko) 항-코로나바이러스에서의 디설피람의 용도
CN1237185C (zh) Sars冠状病毒3cl蛋白酶三维结构模型与抗sars药物
CN113332363B (zh) 茶叶提取物及其组合物在抗冠状病毒中的应用
WO2021164689A1 (zh) 奈非那韦在制备防治新冠肺炎药物中的应用
Shuai et al. An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo
Hemmati et al. Mysterious virus: a review on behavior and treatment approaches of the novel coronavirus, 2019-nCoV
JP7805010B2 (ja) コロナウイルス感染を予防および処置する化合物および方法
CN1237184C (zh) 抗SARS－CoV药物作用靶标、药物筛选方法及抗SARS药物
JP7856325B2 (ja) ウイルス感染を予防および処置するための化合物および方法
Pal et al. Compilation of potential protein targets for SARS-CoV-2: Preparation of homology model and active site determination for future rational antiviral design
Mondal et al. Evaluation of the binding affinity of anti-viral drugs against main protease of SARS-CoV-2 through a molecular docking study
US20210386725A1 (en) Method for inhibiting coronavirus infection and replication
Singh et al. COVID-19: pathophysiology, transmission, and drug development for therapeutic treatment and vaccination strategies
CN113893345A (zh) 247种化合物及其组合物在抗新型冠状病毒感染中的应用
CN112294793B (zh) 氯生太尔或其药学上可接受的盐在制备用于预防和/或治疗冠状病毒感染的药物中的应用
US20230241067A1 (en) Targeting papain-like protease for broad-spectrum coronaviruses inhibition
US20250214981A1 (en) Compound and application thereof in preparation of medicine for treating enterovirus-related diseases
JP2023535714A (ja) ウイルス感染を阻害するための方法および組成物
RU2829731C1 (ru) Применение дисульфирама при резистентности коронавируса
Barile et al. Therapeutic targeting of coronavirus spike glycoprotein priming